Trans‐Apical Transcatheter Aortic Valve Replacement in a Dialysis Patient with Systolic Heart Failure

Akira Oshima; Teruhiko Imamura; Hiroshi Onoda; Yohei Ueno; Ryuichi Ushijima; Mitsuo Sobajima; Nobuyuki Fukuda; Shigeki Yokoyama; Toshio Doi; Kazuaki Fukahara; Hiroshi Ueno; Koichiro Kinugawa

doi:10.3390/medicina58030347

Trans‐Apical Transcatheter Aortic Valve Replacement in a Dialysis Patient with Systolic Heart Failure

Akira Oshima, Teruhiko Imamura^*, Hiroshi Onoda, Yohei Ueno, Ryuichi Ushijima, Mitsuo Sobajima, Nobuyuki Fukuda, Shigeki Yokoyama, Toshio Doi, Kazuaki Fukahara, Hiroshi Ueno, Koichiro Kinugawa

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Mortality and morbidity remain high following transcatheter aortic valve replacement (TAVR) in dialysis patients or those with low left ventricular ejection fraction. Therapeutic strategy for those with these comorbidities remains unestablished. We had a dialysis patient with peripheral artery disease and low left ventricular ejection fraction, who received successfully scheduled transapical TAVR following sufficient reverse remodeling by 3‐month optimal medical therapy. Our strategy should be validated in a larger robust cohort.

Original language	English
Article number	347
Journal	Medicina (Lithuania)
Volume	58
Issue number	3
DOIs	https://doi.org/10.3390/medicina58030347
State	Published - 2022/03

Keywords

Aortic stenosis
Heart failure
Valvular disease

ASJC Scopus subject areas

General Medicine

Access to Document

10.3390/medicina58030347

Cite this

@article{9d43ab01b6fd45dba8032d5ce88ac7a9,

title = "Trans‐Apical Transcatheter Aortic Valve Replacement in a Dialysis Patient with Systolic Heart Failure",

abstract = "Mortality and morbidity remain high following transcatheter aortic valve replacement (TAVR) in dialysis patients or those with low left ventricular ejection fraction. Therapeutic strategy for those with these comorbidities remains unestablished. We had a dialysis patient with peripheral artery disease and low left ventricular ejection fraction, who received successfully scheduled transapical TAVR following sufficient reverse remodeling by 3‐month optimal medical therapy. Our strategy should be validated in a larger robust cohort.",

keywords = "Aortic stenosis, Heart failure, Valvular disease",

author = "Akira Oshima and Teruhiko Imamura and Hiroshi Onoda and Yohei Ueno and Ryuichi Ushijima and Mitsuo Sobajima and Nobuyuki Fukuda and Shigeki Yokoyama and Toshio Doi and Kazuaki Fukahara and Hiroshi Ueno and Koichiro Kinugawa",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = mar,

doi = "10.3390/medicina58030347",

language = "英語",

volume = "58",

journal = "Medicina (Lithuania)",

issn = "1010-660X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Trans‐Apical Transcatheter Aortic Valve Replacement in a Dialysis Patient with Systolic Heart Failure

AU - Oshima, Akira

AU - Imamura, Teruhiko

AU - Onoda, Hiroshi

AU - Ueno, Yohei

AU - Ushijima, Ryuichi

AU - Sobajima, Mitsuo

AU - Fukuda, Nobuyuki

AU - Yokoyama, Shigeki

AU - Doi, Toshio

AU - Fukahara, Kazuaki

AU - Ueno, Hiroshi

AU - Kinugawa, Koichiro

PY - 2022/3

Y1 - 2022/3

N2 - Mortality and morbidity remain high following transcatheter aortic valve replacement (TAVR) in dialysis patients or those with low left ventricular ejection fraction. Therapeutic strategy for those with these comorbidities remains unestablished. We had a dialysis patient with peripheral artery disease and low left ventricular ejection fraction, who received successfully scheduled transapical TAVR following sufficient reverse remodeling by 3‐month optimal medical therapy. Our strategy should be validated in a larger robust cohort.

AB - Mortality and morbidity remain high following transcatheter aortic valve replacement (TAVR) in dialysis patients or those with low left ventricular ejection fraction. Therapeutic strategy for those with these comorbidities remains unestablished. We had a dialysis patient with peripheral artery disease and low left ventricular ejection fraction, who received successfully scheduled transapical TAVR following sufficient reverse remodeling by 3‐month optimal medical therapy. Our strategy should be validated in a larger robust cohort.

KW - Aortic stenosis

KW - Heart failure

KW - Valvular disease

UR - http://www.scopus.com/inward/record.url?scp=85125337792&partnerID=8YFLogxK

U2 - 10.3390/medicina58030347

DO - 10.3390/medicina58030347

M3 - 学術論文

C2 - 35334522

AN - SCOPUS:85125337792

SN - 1010-660X

VL - 58

JO - Medicina (Lithuania)

JF - Medicina (Lithuania)

IS - 3

M1 - 347

ER -

Trans‐Apical Transcatheter Aortic Valve Replacement in a Dialysis Patient with Systolic Heart Failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this